1
|
Li N, Li C, Han R, Wang Y, Yang M, Wang H, Tian J. LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain. Front Pharmacol 2019; 10:53. [PMID: 30837867 PMCID: PMC6382704 DOI: 10.3389/fphar.2019.00053] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 01/18/2019] [Indexed: 11/13/2022] Open
Abstract
Background and Purpose: Sedation and somnolence remain serious adverse effects of the existing analgesics (e.g., pregabalin, duloxetine) for neuropathic pain. The available evidence indicates that serotonin (5-HT), noradrenaline (NE), and dopamine (DA) play important roles in modulating the descending inhibitory pain pathway and sleep-wake cycle. The aim of this work was to test the hypothesis that LPM580098, a novel triple reuptake inhibitor (TRI) of 5-HT, NE, and DA, has analgesic effect, and does not induce significant adverse effects associated with central inhibition, such as sedation and somnolence. Methods: The analgesic activity of LPM580098 was assessed on formalin test and spinal nerve ligation (SNL)-induced neuropathic pain model. Locomotor activity, pentobarbital sodium-induced sleeping and rota-rod tests were also conducted. In vitro binding and uptake assays, and Western blotting were performed to examine the potential mechanisms. Results: LPM580098 suppressed the nocifensive behaviors during phase II of the formalin test in mice. In SNL rats, LPM580098 (16 mg kg-1) inhibited mechanical allodynia, thermal hyperalgesia and hyperexcitation of wide-dynamic range (WDR) neurons, in which the effect of LPM580098 was similar to pregabalin (30 mg kg-1). However, pregabalin altered the spontaneous locomotion, affected pentobarbital sodium-induced sleep, and showed a trend to perform motor dysfunction, which were not induced by LPM580098. Mechanistically, LPM580098 inhibited the uptake of 5-HT, NE, and DA, improved pain-induced changes of the synaptic functional plasticity and structural plasticity possibly via downregulating the NR2B/CaMKIIα/GluR1 and Rac1/RhoA signaling pathways. Conclusion: Our results suggest that LPM580098, a novel TRI, is effective in attenuating neuropathic pain without producing unwanted sedation and somnolence associated with central nervous system (CNS) depressants.
Collapse
Affiliation(s)
- Nannan Li
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China
| | - Chunmei Li
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China
| | - Rui Han
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China
| | - Yu Wang
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China
| | - Mina Yang
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China
| | - Hongbo Wang
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China
| | - Jingwei Tian
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China
| |
Collapse
|
2
|
Guo W, Gao Y, Jiang W, Li C, Lin F, Zhu H, Wang H, Ye L, Qi JG, Cen X, Tian J. Toxicity effects of a novel potent triple reuptake inhibitor, LPM570065, on the fertility and early embryonic development in Sprague-Dawley rats. Regul Toxicol Pharmacol 2018; 100:45-51. [PMID: 30359699 DOI: 10.1016/j.yrtph.2018.10.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2018] [Revised: 10/08/2018] [Accepted: 10/20/2018] [Indexed: 02/05/2023]
Abstract
Selective serotonin reuptake inhibitors (SSRIs) have developed as novel antidepressants and have been determined to possess higher efficacy and less adverse effects compared to other antidepressants. Our previous studies have showed that LPM570065, a new potent TRI, is relatively nontoxic in acute, subchronic toxicity and genotoxicity evaluations. In the current study, toxicity of LPM570065 was further evaluated on the fertility and early embryonic development in Sprague-Dawley rats. A total of 264 rats were treated with various concentrations of LPM570065 (30 mg/kg, 100 mg/kg, and 300 mg/kg) or used as control. Females rats were treated for two consecutive weeks, followed by mating via cohabitation up to the 7th gestation day (GD). The male rats were treated for four consecutive weeks, which were followed by first mating with treated female rats. Then, all males were treated up to the 9th week and followed by second mating with non-treated female rats, and were sacrificed. All surviving pregnant females were euthanized on GD 15. We evaluated the following parameters, namely, mortality, toxicity symptoms, body weight, amount of food consumed, sexual cycle, mating behavior, pregnancy, sperm production, gross necropsy, and weight of organs. Excessive salivation was observed post treatment in nearly all females and males in the 100 and 300 mg/kg LPM570065 treatment groups. Body weight gain was decreased in gravid rats treated with 300 mg/kg LPM570065 during GD 0-6 (P < 0.05). The application of 300 mg/kg of LPM57006 to male rats induced a decrease in implantation sites and lower fertility rates (P < 0.05). However, sperm concentration and count were higher in the LPM570065-treated groups (30 mg/kg, 100 mg/kg, and 300 mg/kg) compared to the controls. Moreover, duration of mating significantly decreased to 37.5% after nine weeks of LPM570065 treatment at a concentration of 300 mg/kg (P < 0.05). In conclusion, the no observable adverse effect level (NOAEL) was established at 100 mg/kg and 300 mg/kg for female and male rats, respectively. The NOAEL for fertility and early embryonic development was established at 300 mg/kg and 100 mg/kg for female and male rats, respectively.
Collapse
Affiliation(s)
- Wei Guo
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Yantai University, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, PR China
| | - Yonglin Gao
- School of Life Sciences, Yantai University, Yantai, 264005, PR China
| | - Wanglin Jiang
- School of Pharmacy, Binzhou Medical University, Yantai, 264003, PR China
| | - Chunmei Li
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Yantai University, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, PR China
| | - Fei Lin
- State Key Laboratory of Long-acting Targeting Drug Delivery Technologies, Luye Pharma Group Ltd., Yantai, 264003, PR China
| | - Haibo Zhu
- School of Public Health and Management, Binzhou Medical University, Yantai, 264003, PR China
| | - Hongbo Wang
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Yantai University, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, PR China
| | - Liang Ye
- School of Public Health and Management, Binzhou Medical University, Yantai, 264003, PR China
| | - Jia Grace Qi
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Yantai University, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, PR China
| | - Xiaobo Cen
- National Chengdu Center for Safety Evaluation of Drugs, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu, 610041, PR China.
| | - Jingwei Tian
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Yantai University, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, PR China.
| |
Collapse
|
3
|
A novel prodrug strategy to improve the oral absorption of O-desmethylvenlafaxine. Exp Ther Med 2016; 12:1611-1617. [PMID: 27588083 DOI: 10.3892/etm.2016.3453] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2015] [Accepted: 04/11/2016] [Indexed: 01/13/2023] Open
Abstract
O-Desmethylvenlafaxine (desvenlafaxine, ODV) is the active metabolite of venlafaxine, with similar activity and less risk for pharmacokinetic drug interactions compared to its parent compound venlafaxine. The purpose of this study was to design a series of esters of ODV and assess their potential as ODV prodrugs with improved bioavailability and brain uptake. Seven esters were synthesized and pharmacokinetic screening was performed in rats. The monoester formed on the phenolic hydroxyl of ODV (ODVP-1, ODVP-2, ODVP-3 and ODVP-5) could be degraded to ODV in rat plasma. These four compounds confirmed as possible prodrugs were then studied to evaluated the relative bioavailability of ODV they produced in beagle dogs. ODVP-1, ODVP-2 and ODVP-3 demonstrated higher relative bioavailability of ODV. Finally, ODVP-1, ODVP-2 and ODVP-3 were studied to evaluate their brain uptake in rats. The concentration of ODV in the rat plasma, brain and hypothalamus after administration of ODVP-1, ODVP-2 or ODVP-3 was higher compared with that of ODV. The higher bioavailability, improved pharmacokineics properties and more rapid penetration and translation of ODV suggest that ODVP-1, ODVP-2 or ODVP-3 may warrant further development and application as ODV prodrugs.
Collapse
|
4
|
Zhang F, Shao J, Tian J, Zhong Y, Ye L, Meng X, Liu Q, Wang H. Antidepressant-like Effects of LPM580153, A Novel Potent Triple Reuptake Inhibitor. Sci Rep 2016; 6:24233. [PMID: 27052887 PMCID: PMC4823741 DOI: 10.1038/srep24233] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Accepted: 03/22/2016] [Indexed: 12/04/2022] Open
Abstract
The purpose of this study was to characterize a novel compound, 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl) ethyl] phenyl 3-nitrophenyl ether, designated LPM580153. We used several well-validated animal models of depression to assess the antidepressant-like activity of LPM580153, followed by a neurotransmitter uptake assay and a corticosterone-induced cell injury model to explore its mechanism of action. In mice, LPM580153 reduced immobility time in the tail suspension test, and in rats subjected to chronic unpredictable mild stress it reversed reductions in body weight gain and ameliorated anhedonia. The neurotransmitter uptake assay results demonstrated that LPM580153 inhibited the uptake of serotonin, norepinephrine and dopamine. Furthermore, LPM580153 protected the SH-SY5Y cells against the cytotoxic activity of corticosterone, an action that might be related to the role of LPM580153 in increasing the protein levels of BDNF, p-ERK1/2, p-AKT, p-CREB and p-mTOR. Together, these findings indicate that LPM580153 is a novel triple reuptake inhibitor with robust antidepressant-like effects.
Collapse
Affiliation(s)
- Fangxi Zhang
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China
| | - Jing Shao
- The third hospital of Jinan, Jinan, 250132, PR China
| | - Jingwei Tian
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China
| | - Yan Zhong
- Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, 210009, PR China
| | - Liang Ye
- School of Public Health and Management, Binzhou Medical University, Yantai, Shandong, PR China
- Institute of Toxicology, Binzhou Medical University, Yantai, Shandong, PR China
| | - Xiangjing Meng
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China
| | - Qiaofeng Liu
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China
| | - Hongbo Wang
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China
| |
Collapse
|
5
|
Zhang X, Wang M, Li P, Wang A, Liang R, Gai Y, Liu W, Li Y, Sun K. Application of hot-melt extrusion technology for designing an elementary osmotic pump system combined with solid dispersion for a novel poorly water-soluble antidepressant. Pharm Dev Technol 2015; 21:1006-1014. [DOI: 10.3109/10837450.2015.1089896] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Xuemei Zhang
- Department of Pharmaceutics, School of Pharmacy, Yantai University, Yantai, People’s Republic of China and
| | - Meng Wang
- Department of Pharmaceutics, School of Pharmacy, Yantai University, Yantai, People’s Republic of China and
| | - Pei Li
- Department of Pharmaceutics, School of Pharmacy, Yantai University, Yantai, People’s Republic of China and
| | - Aiping Wang
- Department of Pharmaceutics, School of Pharmacy, Yantai University, Yantai, People’s Republic of China and
| | - Rongcai Liang
- Department of Pharmaceutics, School of Pharmacy, Yantai University, Yantai, People’s Republic of China and
| | - Yunyun Gai
- State Key Laboratory of Long-Acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co., Ltd., Yantai, People’s Republic of China
| | - Wanhui Liu
- Department of Pharmaceutics, School of Pharmacy, Yantai University, Yantai, People’s Republic of China and
| | - Youxin Li
- Department of Pharmaceutics, School of Pharmacy, Yantai University, Yantai, People’s Republic of China and
- State Key Laboratory of Long-Acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co., Ltd., Yantai, People’s Republic of China
| | - Kaoxiang Sun
- Department of Pharmaceutics, School of Pharmacy, Yantai University, Yantai, People’s Republic of China and
| |
Collapse
|
6
|
Experimental Malaria in Pregnancy Induces Neurocognitive Injury in Uninfected Offspring via a C5a-C5a Receptor Dependent Pathway. PLoS Pathog 2015; 11:e1005140. [PMID: 26402732 PMCID: PMC4581732 DOI: 10.1371/journal.ppat.1005140] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Accepted: 08/11/2015] [Indexed: 02/06/2023] Open
Abstract
The in utero environment profoundly impacts childhood neurodevelopment and behaviour. A substantial proportion of pregnancies in Africa are at risk of malaria in pregnancy (MIP) however the impact of in utero exposure to MIP on fetal neurodevelopment is unknown. Complement activation, in particular C5a, may contribute to neuropathology and adverse outcomes during MIP. We used an experimental model of MIP and standardized neurocognitive testing, MRI, micro-CT and HPLC analysis of neurotransmitter levels, to test the hypothesis that in utero exposure to malaria alters neurodevelopment through a C5a-C5aR dependent pathway. We show that malaria-exposed offspring have persistent neurocognitive deficits in memory and affective-like behaviour compared to unexposed controls. These deficits were associated with reduced regional brain levels of major biogenic amines and BDNF that were rescued by disruption of C5a-C5aR signaling using genetic and functional approaches. Our results demonstrate that experimental MIP induces neurocognitive deficits in offspring and suggest novel targets for intervention. A growing body of evidence has established the importance of the in utero environment on neurodevelopment and long-term cognitive and behavioral outcomes. These data suggest factors that disrupt the tightly regulated in utero environment can modify normal neurodevelopmental processes. Approximately 125 million pregnancies worldwide are at risk of malaria infection every year. However the impact of in utero exposure to MIP on fetal neurodevelopment is unknown. Here we use a mouse model of malaria in pregnancy to examine the impact of maternal malaria exposure on neurocognitive outcomes in offspring. We observed impaired learning and memory and depressive-like behavior in malaria-exposed offspring that were neither congenitally infected nor low birth weight. These neurocognitive impairments were associated with decreased tissue levels of neurotransmitters in regions of the brain linked to the observed deficits. Disruption of maternal C5a complement receptor signaling restored the levels of neurotransmitters and rescued the associated cognitive phenotype observed in malaria-exposed offspring. This study provides the first evidence implicating a causal link between pre-natal exposure to malaria, complement signaling and subsequent neurocognitive impairment in offspring.
Collapse
|
7
|
Fan G, Cao Y, Yang J. In vitroinhibition and induction of human cytochrome P450 enzymes by SIPI5357, a potential antidepressant. Biopharm Drug Dispos 2015; 36:364-372. [DOI: 10.1002/bdd.1947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Revised: 02/09/2015] [Accepted: 03/04/2015] [Indexed: 11/09/2022]
Affiliation(s)
- Gaoning Fan
- Center of Drug Metabolism and Pharmacokinetics; China Pharmaceutical University; 24# Tong Jia Xiang Nanjing China
| | - Yun Cao
- Center of Drug Metabolism and Pharmacokinetics; China Pharmaceutical University; 24# Tong Jia Xiang Nanjing China
| | - Jin Yang
- Center of Drug Metabolism and Pharmacokinetics; China Pharmaceutical University; 24# Tong Jia Xiang Nanjing China
| |
Collapse
|
8
|
Hou J, Xing Y, Zuo D, Wu Y, Tian J, Meng Q, Yang M. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor. Physiol Behav 2015; 138:141-9. [DOI: 10.1016/j.physbeh.2014.10.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2014] [Revised: 06/14/2014] [Accepted: 10/09/2014] [Indexed: 12/13/2022]
|
9
|
Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L. Sci Rep 2014; 4:5632. [PMID: 25005489 PMCID: PMC4088061 DOI: 10.1038/srep05632] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2014] [Accepted: 06/20/2014] [Indexed: 11/17/2022] Open
Abstract
Adhyperforin is a novel constituent of Hypericum perforatum L., but its antidepressant-like activity remains unclear. To explore that, several well-validated animal models of depression as well as neurotransmitter reuptake and transporter binding assays were conducted. The results showed adhyperforin could reduce the immobility time of mice in the forced swimming test and tail suspension assay, antagonize the behaviors induced by reserpine, and have no effect on locomotor activity. Furthermore, following establishment of a chronic unpredictable mild stress model, adhyperforin increased the number of crossings and rearings in rats in the open field test and increased the sucrose consumption. Finally, adhyperforin inhibited uptake of serotonin, norepinephrine, and dopamine, and displayed robust binding affinities for the serotonin and norepinephrine transporters. Overall, the current study provides the first evidence that adhyperforin is a novel, active ingredient of Hypericum perforatum L. with robust antidepressant-like activity.
Collapse
|
10
|
Zhang R, Li X, Shi Y, Shao Y, Sun K, Wang A, Sun F, Liu W, Wang D, Jin J, Li Y. The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats. PLoS One 2014; 9:e91775. [PMID: 24614602 PMCID: PMC3948889 DOI: 10.1371/journal.pone.0091775] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Accepted: 02/13/2014] [Indexed: 11/19/2022] Open
Abstract
Triple reuptake inhibitors (TRIs) are currently being developed as a new class of promising antidepressants that block serotonin (5-HT), dopamine (DA) and norepinephrine (NE) transporters, thereby increasing extracellular monoamine concentrations. The purpose of this study was to investigate the effects of LPM570065, a novel TRI and a desvenlafaxine prodrug, on extracellular 5-HT, DA and NE levels in the rat striatum after acute and chronic administration relative to desvenlafaxine, using High Performance Liquid Chromatography (HPLC) and microdialysis. Acute administration was performed by providing rodents with oral solutions (0.06 mmol·kg(-1) p.o.), oral suspensions (0.06 mmol·kg(-1) p.o.) and intravenous solutions (0.04 mmol·kg(-1) i.v.) of LPM570065 and desvenlafaxine. Oral suspensions (0.06 mmol·kg(-1)·day(-1)) of the two drugs were also administered for a 14-day chronic period. HPLC analysis revealed that LPM570065 rapidly penetrated the rat striatum, converted into desvenlafaxine and exhibited larger total exposure compared with the administration of desvenlafaxine. Microdialysis revealed that acute and chronic administration of oral suspension of LPM570065 increased the 5-HT, DA and NE levels more than the relative administration of desvenlafaxine. Unlike desvenlafaxine, acute administration of an intravenous LPM570065 solution did not induce the undesirable 90% decrease in extracellular 5-HT levels. In contrast to the fully dose-dependent elevation of 5-HT induced by desvenlafaxine, the acute administration of LPM570065 showed a capped increase in extracellular 5-HT levels when combined with WAY-100635. Additionally, forced swim test demonstrated that acute and chronic administration of LPM570065 reduced the immobility time more than the relative administration of desvenlafaxine. These data suggest that LPM570065 may have greater efficacy and/or a more rapid onset of antidepressant action than desvenlafaxine and also counterbalance the harmful effects of desvenlafaxine on 5-HT neurotransmission related to 5-HT1A autoreceptors. Thus, this new class of drugs, TRIs has the potential to provide a new therapeutic mechanism for treating depression.
Collapse
Affiliation(s)
- Renyu Zhang
- School of Life Sciences, Jilin University, Changchun, Jilin Province, China
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Company Limited, Yantai, Shandong Province, China
| | - Xiang Li
- School of Life Sciences, Jilin University, Changchun, Jilin Province, China
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Company Limited, Yantai, Shandong Province, China
| | - Yanan Shi
- School of Life Sciences, Jilin University, Changchun, Jilin Province, China
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Company Limited, Yantai, Shandong Province, China
| | - Yufeng Shao
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Company Limited, Yantai, Shandong Province, China
| | - Kaoxiang Sun
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Company Limited, Yantai, Shandong Province, China
- School of Pharmacy, Yantai University, Yantai, Shandong Province, China
| | - Aiping Wang
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Company Limited, Yantai, Shandong Province, China
- School of Pharmacy, Yantai University, Yantai, Shandong Province, China
| | - Fengying Sun
- School of Life Sciences, Jilin University, Changchun, Jilin Province, China
| | - Wanhui Liu
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Company Limited, Yantai, Shandong Province, China
- School of Pharmacy, Yantai University, Yantai, Shandong Province, China
| | - Di Wang
- School of Life Sciences, Jilin University, Changchun, Jilin Province, China
| | - Jingji Jin
- School of Life Sciences, Jilin University, Changchun, Jilin Province, China
- * E-mail: (YL); (JJ)
| | - Youxin Li
- School of Life Sciences, Jilin University, Changchun, Jilin Province, China
- State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Company Limited, Yantai, Shandong Province, China
- School of Pharmacy, Yantai University, Yantai, Shandong Province, China
- * E-mail: (YL); (JJ)
| |
Collapse
|
11
|
Zhang Y, Yang Y, Zhao S, Yang Z, Yang H, Fawcett JP, Li Y, Gu J, Sun T. Phenolic esters of O-desmethylvenlafaxine with improved oral bioavailability and brain uptake. Molecules 2013; 18:14920-34. [PMID: 24304586 PMCID: PMC6270635 DOI: 10.3390/molecules181214920] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2013] [Revised: 12/02/2013] [Accepted: 12/02/2013] [Indexed: 11/16/2022] Open
Abstract
O-Desmethylvenlafaxine (desvenlafaxine, ODV) is a recently approved antidepressant which in some clinical studies failed to meet a satisfactory end-point. The aim of this study was to prepare a series of phenolic esters of ODV and evaluate their potential as ODV prodrugs with improved brain uptake. Fifteen phenolic esters (compounds 1a-o) were synthesized and their pharmacokinetic profiles evaluated in rat. The four compounds producing the highest relative bioavailability of ODV in rat (compounds 1c, 1e, 1n, 1o) were then studied to evaluate their brain uptake. Of these four compounds, compound 1n (the piperonylic acid ester of ODV) demonstrated the highest C(max) of ODV both in the rat hypothalamus and total brain. Finally the pharmacokinetics of 1n were evaluated in beagle dog where the increase in relative bioavailability of ODV was found to be as great as in rat. This high relative bioavailability of ODV coupled with its good brain penetration make 1n the most promising candidate for development as an ODV prodrug.
Collapse
Affiliation(s)
- Yang Zhang
- Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, Shenyang 110016, China
- Research Center for Drug Metabolism, College of Life Sciences, Jilin University, Changchun 130021, China
- School of Chemical and Pharmaceutical Engineering, Jilin Institute of Chemical Technology, Jilin 132022, China
| | - Yan Yang
- Research Center for Drug Metabolism, College of Life Sciences, Jilin University, Changchun 130021, China
| | - Sen Zhao
- Research Center for Drug Metabolism, College of Life Sciences, Jilin University, Changchun 130021, China
| | - Zhichao Yang
- Research Center for Drug Metabolism, College of Life Sciences, Jilin University, Changchun 130021, China
| | - Hong Yang
- Research Center for Drug Metabolism, College of Life Sciences, Jilin University, Changchun 130021, China
| | - J. Paul Fawcett
- School of Pharmacy, University of Otago, PO Box 56, Dunedin 9054, New Zealand
| | - Youxin Li
- Research Center for Drug Metabolism, College of Life Sciences, Jilin University, Changchun 130021, China
| | - Jingkai Gu
- Research Center for Drug Metabolism, College of Life Sciences, Jilin University, Changchun 130021, China
| | - Tiemin Sun
- Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, Shenyang 110016, China
| |
Collapse
|
12
|
Leggio GM, Salomone S, Bucolo C, Platania C, Micale V, Caraci F, Drago F. Dopamine D3 receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 2013; 719:25-33. [DOI: 10.1016/j.ejphar.2013.07.022] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2013] [Revised: 06/05/2013] [Accepted: 07/01/2013] [Indexed: 12/12/2022]
|
13
|
A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances. Neuropharmacology 2013; 73:183-91. [DOI: 10.1016/j.neuropharm.2013.04.060] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2013] [Revised: 04/25/2013] [Accepted: 04/28/2013] [Indexed: 12/23/2022]
|
14
|
Abstract
Depression is a potentially life-threatening mental disorder affecting approximately 300 million people worldwide. Despite much effort, the molecular underpinnings of clinical depression remain poorly defined, and current treatments carry limited therapeutic efficacy and potentially burdensome side effects. Recently, small noncoding RNA molecules known as microRNA (miRNA) have gained prominence as a target for therapeutic intervention, given their capacity to regulate neuronal physiology. Further, mounting evidence suggests a prominent role for miRNA in depressive molecular signaling. Recent studies have demonstrated that dysregulation of miRNA expression occurs in animal models of depression, and in the post-mortem tissue of clinically depressed patients. Investigations into depression-associated miRNA disruption reveals dramatic effects on downstream targets, many of which are thought to contribute to depressive symptoms. Furthermore, selective serotonin reuptake inhibitors, as well as other antidepressant drugs, have the capacity to reverse aberrant depressive miRNA expression and their downstream targets. Given the powerful effects that miRNA have on the central nervous system transcriptome, and the aforementioned studies, there is a compelling rationale to begin to assess the potential contribution of miRNA to depressive etiology. Here, we review the molecular biology of miRNA, our current understanding of miRNA in relation to clinical depression, and the utility of targeting miRNA for antidepressant treatment.
Collapse
Affiliation(s)
- Katelin F Hansen
- Department of Neuroscience, Ohio State University, Columbus, OH, USA
| | | |
Collapse
|
15
|
Zheng YY, Xie P, Xing LX, Wang JY, Li JQ. Development and Practical Synthesis of a Triple Reuptake Inhibitor, (1R,2S)-SIPI 5357. Org Process Res Dev 2012. [DOI: 10.1021/op300258w] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yong-Yong Zheng
- Novel Technology Center of Pharmaceutical Chemistry,
Shanghai Institute of Pharmaceutical Industry, Shanghai Engineering Research Center of Pharmaceutical Process, 1111 North Zhongshan No.1 Road, Shanghai 200437, P.R. of China
| | - Peng Xie
- Novel Technology Center of Pharmaceutical Chemistry,
Shanghai Institute of Pharmaceutical Industry, Shanghai Engineering Research Center of Pharmaceutical Process, 1111 North Zhongshan No.1 Road, Shanghai 200437, P.R. of China
| | - Long-Xuan Xing
- Novel Technology Center of Pharmaceutical Chemistry,
Shanghai Institute of Pharmaceutical Industry, Shanghai Engineering Research Center of Pharmaceutical Process, 1111 North Zhongshan No.1 Road, Shanghai 200437, P.R. of China
| | - Jing-Yu Wang
- Novel Technology Center of Pharmaceutical Chemistry,
Shanghai Institute of Pharmaceutical Industry, Shanghai Engineering Research Center of Pharmaceutical Process, 1111 North Zhongshan No.1 Road, Shanghai 200437, P.R. of China
| | - Jian-Qi Li
- Novel Technology Center of Pharmaceutical Chemistry,
Shanghai Institute of Pharmaceutical Industry, Shanghai Engineering Research Center of Pharmaceutical Process, 1111 North Zhongshan No.1 Road, Shanghai 200437, P.R. of China
| |
Collapse
|